Search for news or symbols

Summary Conversations Statistics Historical Data Profile Financials Analysis Options

CDXS - Codexis, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Follow

3.9898
-0.1602 (-3.8602%) As of 09:37AM EST. Market open.

Red Green Area Full screen

1D 5D 1M 6M YTD 1Y 5Y Max
:
 Previous Close 4.1500

Open 3.4100

Bid 3.9200 x 1000

Ask 4.2000 x 900

Day's Range 3.9750 - 4.1800

52 Week Range 1.4500 - 5.0700

Volume 91,712

Avg. Volume 744,693

Market Cap 278.706M

Beta (5Y Monthly) 1.89

PE Ratio (TTM) N/A

EPS (TTM) -1.2100

Earnings Date Feb 28, 2024

Forward Dividend & Yield N/A (N/A)

Ex-Dividend Date N/A

1y Target Est 6.00

All News Press Releases SEC Filings

:
 CDXS

Codexis Enters Exclusive Licensing Agreement for Newly Engineered

Double-Stranded DNA Ligase with Roche
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading
enzyme engineering company, today announced it has entered into an agreement with Roche for an
exclusive, global license for the Company’s newly engineered double-stranded DNA (dsDNA) ligase for
next-generation sequencing (NGS) library preparation and the Company’s EvoT4™ DNA ligase. Under the
terms of the deal, Codexis will receive upfront and technical milestone payments. This deal supersedes
the pr

GlobeNewswire • yesterday

7-Figure Investor Reveals: Top Stocks To Watch In 2024

Ad Wealth Academy

CDXS

Codexis to Participate in TD Cowen 44th Annual Health Care

Conference
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading
enzyme engineering company, today announced the Company will attend the TD Cowen 44th Annual
Health Care Conference, being held March 4-6, 2024, in Boston, Massachusetts. Management will
participate in a fireside chat on Monday, March 4, 2024, at 2:50 pm ET. A live webcast of the event will be
available here and in the Investor Relations section of the Company’s website, http://ir.codexis.com. A
repla
:
 GlobeNewswire • 2 days ago

CDXS

Codexis Announces Appointment of Masad Damha, PhD, and Jim

Lalonde, PhD, to Strategic Advisory Board
Board expertise encompasses oligonucleotide research, development, manufacturing and
commercialization to support development of ECO Synthesis™ manufacturing platform Masad Damha,
PhD Dr. Masad Damha, Codexis Strategic Advisory Board Member Jim Lalonde, PhD Dr. Jim Lalonde,
Codexis Strategic Advisory Board Member REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) --
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the
appointment of Masad Damha, PhD, and Jim

GlobeNewswire • 8 days ago

CDXS

Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial

:
 Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial
Results on February 28
REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading
enzyme engineering company, today announced that it will report its financial results for the fourth
quarter and fiscal year 2023 on Wednesday, February 28, 2024, following the close of market. Codexis
management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s
financial results and provide a business update. Participants may access the live webcast on the Codex

GlobeNewswire • 13 days ago

CDXS

Codexis Secures $40 Million in Strategic Financing Deal with Innovatus

Capital Partners to Further Strengthen Cash Position Ahead of Key
Milestones
Term loan agreement enables Company to accelerate development and enhance commercialization of
ECO Synthesis™ manufacturing platform for RNAi therapeutics Financing bolsters cash position and
provides additional flexibility on projected runway through positive cash-flow around end of 2026
Codexis management to host conference call today at 4:30 pm ET REDWOOD CITY, Calif., Feb. 13, 2024
(GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today
announced it has

GlobeNewswire • 14 days ago

Do You Know How Sleep Affects Your Mood?

:
 Ad Health Promotion Board

CDXS

seqWell and Codexis to Unveil Engineered Transposase Enzyme for

Genomics Applications at AGBT General Meeting
TnX transposase development collaboration leverages strengths of both companiesBEVERLY, Mass. and
REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- seqWell, a global provider of genomic library
workflow solutions, and Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today
announced the creation of an engineered high-performance transposase enzyme designed to drive
superior performance in sequencing applications. The co-development of this new transposase enzyme –
called

GlobeNewswire • 26 days ago

CDXS

The past three years for Codexis (NASDAQ:CDXS) investors has not
been profitable
It is a pleasure to report that the Codexis, Inc. ( NASDAQ:CDXS ) is up 46% in the last quarter. But that
doesn't...

Simply Wall St. • last month

CDXS ^YH103

Baillie Gifford Trims Position in Codexis Inc

:
 On December 1, 2023, Baillie Gifford (Trades, Portfolio), a renowned investment management firm, made
a significant adjustment to its investment portfolio by reducing its stake in Codexis Inc (NASDAQ:CDXS).
Following this transaction, Baillie Gifford (Trades, Portfolio)'s remaining holding in Codexis Inc totals
3,419,093 shares, which represents a 4.90% ownership in the company and a 0.01% position in Baillie
Gifford (Trades, Portfolio)'s portfolio.

GuruFocus.com • 2 months ago

CDXS

Codexis Announces Purchase Agreement with Nestlé Health Science

for CDX-7108
Company to retain economic interest in biotherapeutic asset while removing cash burn from development
and commercialization costsREDWOOD CITY, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc.
(NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into a purchase
agreement with Nestlé Health Science, a globally recognized leader in the field of nutritional science, for
CDX-7108, an investigational therapy for the potential treatment of exocrine pancreatic insu

GlobeNewswire • 2 months ago

Apple names one of the best memory apps in the world

:
 Ad Neuronation

CDXS

Codexis, Inc. (NASDAQ:CDXS) Stock Rockets 41% But Many Are Still
Ignoring The Company
Codexis, Inc. ( NASDAQ:CDXS ) shares have continued their recent momentum with a 41% gain in the last
month alone...

Simply Wall St. • 2 months ago

: